{"filings":[{"id":470996,"accession_number":"0001193125-26-226751","cik":1841387,"company_name":"Candel Therapeutics, Inc.","ticker":"CADL","form_type":"8-K","filed_at":"2026-05-15T20:13:34+00:00","items":["7.01","9.01"],"status":"ready","headline":"Candel reports 39% improvement in prostate cancer-specific DFS with aglatimagene in phase 3 extended follow-up","event_type":"other_material","confidence":"high","bullets":["Prostate cancer-specific DFS improved 39% vs placebo (HR 0.61, p=0.0031) at median 58-month follow-up.","Consistent favorable trends in TTBF, TTM, metastasis rate, and TTNT in ITT population.","In intermediate-risk subgroup (85% of patients), 90% reduction in time to metastasis (HR 0.1).","Company plans to submit BLA to FDA in Q4 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":78041,"accession_number":"0001193125-26-222892","cik":1841387,"company_name":"Candel Therapeutics, Inc.","ticker":"CADL","form_type":"8-K","filed_at":"2026-05-14T12:15:18+00:00","items":["2.02","9.01"],"status":"ready","headline":"Candel Therapeutics Q1 2026 net loss $8.9M; BLA submission for CAN-2409 on track for Q4 2026","event_type":"earnings","confidence":"high","bullets":["Net loss of $8.9M in Q1 2026 vs net income $7.4M in Q1 2025; R&D expense $9.8M.","Cash and equivalents $194.8M as of March 31, 2026, expected to fund operations into Q1 2028.","Plans to submit BLA for aglatimagene (CAN-2409) in localized prostate cancer in Q4 2026.","Extended follow-up from Phase 2a NSCLC trial shows 50% of patients survived >24 months; Phase 3 NSCLC trial to start June 2026.","Announced commercial partnership with EVERSANA and $100M royalty funding agreement with RTW for potential launch."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109730,"accession_number":"0001193125-26-103126","cik":1841387,"company_name":"Candel Therapeutics, Inc.","ticker":"CADL","form_type":"8-K","filed_at":"2026-03-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Candel reports Q4 2025 net loss of $29.5M; cash $119.7M; plans BLA for aglatimagene in Q4 2026","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 2025: $29.5M vs $14.1M Q4 2024; full year net loss $38.2M vs $55.2M (2024).","Cash $119.7M at Dec 31, 2025; plus $93.5M net from Feb 2026 offering; runway into Q1 2028.","Entered $130M term loan with Trinity Capital; $50M drawn; $100M royalty deal with RTW contingent on FDA approval.","Plan to initiate pivotal phase 3 trial of aglatimagene in NSCLC in Q2 2026; BLA submission for prostate cancer in Q4 2026.","FDA cleared IND for linoserpaturev in recurrent high-grade glioma; mature OS data expected Q4 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109729,"accession_number":"0001193125-26-062490","cik":1841387,"company_name":"Candel Therapeutics, Inc.","ticker":"CADL","form_type":"8-K","filed_at":"2026-02-23T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Candel Therapeutics prices $100M public offering of 18.3M shares at $5.45/share","event_type":"other_material","confidence":"high","bullets":["Gross proceeds $100M from 18,348,624 shares at $5.45; net ~$93.5M base, up to ~$107.6M if option exercised.","Funds will support launch readiness, medical affairs, pre-commercialization for CAN-2409 in early localized prostate cancer and phase 3 trial in NSCLC.","Underwriters granted 30-day option to purchase up to 2,752,293 additional shares at same price.","Offering expected to close Feb 23, 2026; Citigroup, Cantor, Stifel are joint bookrunners.","Pro forma cash runway extended into Q1 2028 based on base net proceeds."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109728,"accession_number":"0001193125-26-059334","cik":1841387,"company_name":"Candel Therapeutics, Inc.","ticker":"CADL","form_type":"8-K","filed_at":"2026-02-19T23:59:59+00:00","items":["1.01","2.02","8.01","7.01","9.01"],"status":"ready","headline":"Candel secures $100M royalty funding from RTW for CAN-2409 prostate cancer launch; prelim cash $119.7M","event_type":"other_material","confidence":"high","bullets":["Candel enters $100M royalty funding deal with RTW; funds available upon FDA approval of CAN-2409 for localized prostate cancer.","RTW receives 4.67% royalty on US net sales ≤$1B, 1.33% above $1B; cap at $250M; ratchet to 6.67% if sales miss targets.","Preliminary cash and equivalents ~$119.7M as of Dec 31, 2025 (unaudited).","BLA submission for CAN-2409 in localized prostate cancer remains on track for Q4 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126259,"accession_number":"0001193125-25-308719","cik":1841387,"company_name":"Candel Therapeutics, Inc.","ticker":"CADL","form_type":"8-K","filed_at":"2025-12-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Candel Therapeutics hosts virtual R&D Day with pipeline overview","event_type":"other_material","confidence":"low","bullets":["Virtual R&D Day held December 5, 2025, from 11:00 am to 1:45 pm ET.","Presentation covers viral immunotherapy approach and oncology-focused pipeline.","Presentation available on investor relations website at https://ir.candeltx.com.","No specific clinical data or financial updates disclosed in the 8-K filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126258,"accession_number":"0001193125-25-279072","cik":1841387,"company_name":"Candel Therapeutics, Inc.","ticker":"CADL","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Candel Q3 net loss $11.3M; cash $87M; secures $130M debt facility with Trinity Capital","event_type":"earnings","confidence":"high","bullets":["Net loss of $11.3M vs $10.6M in Q3 2024; R&D expenses $8.5M, G&A $4.7M.","Cash and equivalents $87.0M as of Sept 30, 2025; plus $50M upfront from Trinity Capital facility to fund operations into Q1 2027.","Entered $130M term loan with Trinity Capital Inc.; $50M drawn at closing, up to $80M additional subject to milestones.","BLA submission for CAN-2409 in localized prostate cancer planned Q4 2026; phase 3 NSCLC trial to start Q2 2026.","Pausing pancreatic cancer program (PDAC) unless external non-dilutive funding obtained."],"consensus_eps_estimate":-0.1888,"consensus_eps_actual":-0.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126257,"accession_number":"0001193125-25-238254","cik":1841387,"company_name":"Candel Therapeutics, Inc.","ticker":"CADL","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["1.01","2.02","2.03","3.02","7.01","8.01","9.01"],"status":"ready","headline":"Candel Therapeutics secures $130M loan; reports positive CAN-3110 survival data","event_type":"other_material","confidence":"high","bullets":["Entered $130M term loan facility with Trinity Capital; $50M drawn at closing, up to $80M additional subject to milestones.","Cash and cash equivalents $87.2M as of Sept 30, 2025; loan carries 10.25% initial rate, 36-month interest-only period.","Phase 1b CAN-3110 interim data: median OS 11.8 months (arm A) and 12.0 months (arm B); two patients alive >40 months post-single injection.","Strategic pivot: seek external partnerships for CAN-2409 in PDAC; focus capital on early localized prostate cancer and NSCLC.","Proceeds to initiate phase 3 CAN-2409 trial in NSCLC in Q2 2026 and support BLA submission for prostate cancer planned Q4 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143005,"accession_number":"0000950170-25-110682","cik":1841387,"company_name":"Candel Therapeutics, Inc.","ticker":"CADL","form_type":"8-K","filed_at":"2025-08-21T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Candel Therapeutics extends office lease through August 2029","event_type":"other_material","confidence":"high","bullets":["Lease term extended from August 31, 2026 to August 31, 2029 for 15,197 sq ft in Needham, MA.","Base rent from Sept 2026: $607,880/yr increasing by ~$15,197 annually to $638,274/yr by lease year 10.","No option to extend beyond the Extended Term; premises accepted 'AS-IS' with no landlord improvements.","The amendment updates base rent schedule and landlord address; no other material changes to lease."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143004,"accession_number":"0000950170-25-108448","cik":1841387,"company_name":"Candel Therapeutics, Inc.","ticker":"CADL","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Candel Q2 net loss $4.8M vs $22.2M loss a year ago; positive phase 3 CAN-2409 results in prostate cancer","event_type":"earnings","confidence":"high","bullets":["Net loss of $4.8M in Q2 2025 vs $22.2M loss in Q2 2024; net other income of $6.4M due to change in warrant liability fair value.","Phase 3 CAN-2409 in localized prostate cancer met primary endpoint with 30% improvement in DFS (HR 0.70, p=0.0155); RMAT designation received.","BLA submission for CAN-2409 in prostate cancer expected in Q4 2026; cash $100.7M sufficient into Q1 2027.","Appointed Charles Schoch as CFO and Maha Radhakrishnan to Board; completed $15M registered direct offering.","Positive overall survival data from phase 2a CAN-2409 in NSCLC (mOS 24.5 months) and pancreatic cancer (mOS 31.4 months)."],"consensus_eps_estimate":-0.1734,"consensus_eps_actual":0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161083,"accession_number":"0001193125-25-145405","cik":1841387,"company_name":"Candel Therapeutics, Inc.","ticker":"CADL","form_type":"8-K","filed_at":"2025-06-24T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Candel Therapeutics raises $15M via registered direct offering of 3.2M shares at $4.67","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$15M from sale of 3,221,395 shares at $4.67/share; closing expected June 25, 2025.","Purchasers include existing healthcare-focused institutional investors, executive officers, and directors.","Net proceeds to support pre-commercialization and launch readiness for CAN-2409 in prostate cancer; BLA submission planned Q4 2026.","Insider participation signals confidence in Candel's strategy and pipeline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161082,"accession_number":"0001193125-25-144204","cik":1841387,"company_name":"Candel Therapeutics, Inc.","ticker":"CADL","form_type":"8-K","filed_at":"2025-06-23T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Candel Therapeutics Appoints Charles Schoch as Permanent CFO, Effective June 20, 2025","event_type":"leadership","confidence":"high","bullets":["Charles Schoch, interim CFO since Jan 2024, promoted to permanent CFO; base salary increased to $440,000, target bonus 40%.","Granted option to purchase 50,000 shares; 25% vests at one year, then ratably over 36 months.","Schoch previously served as VP Finance and Corporate Controller; led capital raise of ~$86M in Q4 2024.","Press release highlights upcoming BLA submission for CAN-2409 in localized prostate cancer.","No family relationships or arrangements with other parties disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161081,"accession_number":"0000950170-25-087696","cik":1841387,"company_name":"Candel Therapeutics, Inc.","ticker":"CADL","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Candel shareholders elect three Class I directors, ratify KPMG as auditor","event_type":"other","confidence":"high","bullets":["Renee Gaeta, Gary J. Nabel, and Joseph C. Papa elected as Class I directors for three-year terms (for/withheld: 13.7M/2.3M, 11.6M/4.4M, 12.8M/3.2M).","Ratification of KPMG as independent auditor for FY2025 passed with 32.2M for, 199K against, 240K abstain.","Broker non-votes on director election totaled 16.7M shares; record date shares outstanding 49.3M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161080,"accession_number":"0000950170-25-082705","cik":1841387,"company_name":"Candel Therapeutics, Inc.","ticker":"CADL","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Candel appoints Maha Radhakrishnan, M.D., to Board; BLA submission for CAN-2409 on track for Q4 2026","event_type":"leadership","confidence":"high","bullets":["Board expanded from 9 to 10 directors; Radhakrishnan named to Class II, term expiring 2026.","Appointment effective June 4, 2025; she receives option for 28,480 shares vesting over 3 years.","Radhakrishnan previously Group SVP and Chief Medical Officer at Biogen (Jan 2020 – Mar 2024).","Candel targets Q4 2026 Biologics License Application submission for CAN-2409 in prostate cancer.","She also serves as Executive Partner at Sofinnova Investments since August 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161079,"accession_number":"0000950170-25-078079","cik":1841387,"company_name":"Candel Therapeutics, Inc.","ticker":"CADL","form_type":"8-K","filed_at":"2025-05-28T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"FDA grants RMAT designation to Candel's CAN-2409 for prostate cancer; phase 3 met endpoint","event_type":"regulatory","confidence":"high","bullets":["RMAT designation for CAN-2409 (aglatimagene besadenovec) in newly diagnosed localized intermediate-to-high-risk prostate cancer.","Phase 3 trial met primary endpoint: 30% risk reduction in disease-free survival (HR 0.70; p=0.0155) vs placebo.","CAN-2409 improved prostate-specific DFS (38% risk reduction; p=0.0046) and pathological complete response (80.4% vs 63.6%; p=0.0015).","Previously granted Fast Track; BLA submission anticipated by end of 2026 with potential rolling/priority review.","Designation provides intensive FDA guidance to expedite development and review of the therapy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161078,"accession_number":"0000950170-25-076458","cik":1841387,"company_name":"Candel Therapeutics, Inc.","ticker":"CADL","form_type":"8-K","filed_at":"2025-05-22T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Candel's CAN-2409 Phase 3 meets primary endpoint (p=0.0155) in localized prostate cancer; ASCO presentation June 3","event_type":"other_material","confidence":"high","bullets":["Statistically significant improvement in DFS (p=0.0155) with 30% risk reduction (HR 0.7) for CAN-2409 plus radiotherapy vs placebo plus radiotherapy.","Secondary endpoints met: 80.4% pathological complete response at two-year biopsy vs 63.6% control (p=0.0015); higher PSA nadir <0.2 ng/ml (67.1% vs 58.6%, p=0.0164).","CAN-2409 well tolerated; treatment-related serious adverse events low (1.7% drug arm vs 2.2% control).","Company plans to submit Biologics License Application for CAN-2409 in Q4 2026.","Data to be presented at ASCO 2025 oral abstract session on June 3, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}